By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gamida Cell Ltd. 

Harey Yehuda 54
P.O.B. 94
Savyon    56530  Israel
Phone: 03-534-7482 Fax: 03-534-3067



Company News
Gamida Cell Receives Additional EMA Orphan Drug Designation For Nicord In Haematopoietic Stem Cell Transplantation (HSCT) 3/23/2017 7:00:49 AM
Gamida Cell Announces First Patient Transplanted In Phase III Registration Study Of Nicord For Blood Cancers 2/28/2017 6:21:05 AM
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016 12/6/2016 12:12:55 PM
Gamida Cell Names Julian Adams, Ph.D. New Chairman Of The Board 11/21/2016 11:16:47 AM
Novartis AG (NVS)-Backed Gamida Cell Nabs Breakthrough Tag for NiCord 10/11/2016 6:16:06 AM
Gamida Cell Announces Appointment Of Julian Adams, Ph.D. And Kenneth I. Moch To Its Board Of Directors 9/15/2016 10:26:51 AM
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016 8:26:15 AM
ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016 6/6/2016 9:36:04 AM
Gamida Cell Announces $4.4 Million Grant From The Israeli Government 5/23/2016 8:38:33 AM
Gamida Cell Presents Additional Positive Data Of NiCord In Blood Cancer Patients At EBMT 2016 4/5/2016 10:32:15 AM